Parnassus Investments, an investment management company, released the “Parnassus Core Equity Fund” fourth quarter 2024 ...

Vertex Pharmaceuticals (VRTX) reachead $495.29 at the closing of the latest trading day, reflecting a +1.42% change compared to its last close.

We recently published a list of the 11 Best Pharma Stocks to Buy According to Hedge Funds. In this article, we are going to ...

Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) was upgraded by analysts at StockNews.com from a “hold” rating to a ...

Shares of Vertex Pharmaceuticals Inc. VRTX rose 1.45% to $495.42 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500 Index SPX rising 0.49% to ...

So far this year the number of companies in the S&P 500 that used the phrase “diversity, equity and inclusion” in annual ...

In a report released today, Gena Wang from Barclays maintained a Buy rating on Legend Biotech (LEGN – Research Report), with a price target of ...

BTIG analyst Mark Massaro lowered the firm’s price target on MaxCyte (MXCT) to $6 from $8 and keeps a Buy rating on the shares after its Q4 ...

Vertex Pharmaceuticals EVP Ourania Tatsis sold 3,242 shares worth $1.62 million under a pre-arranged plan. The sale, executed on March 10, 2025, priced each share at $499.99, with Tatsis still holding ...

Tariff worries pushed the ASX down, coal took a hit after Macquarie's call, while gold climbed as the market edged closer to ...

Funded by investors such as Flagship and General Catalyst, the AI startup claims its platform will help scientists speed up ...

OpenAI engineers say the new tools will help enterprises more easily build agents with advanced reasoning and multimodal ...